DB1 REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE  by Brixner, D et al.
RESULTS: The incidence of major bleeding among 4005 Medi-
care beneﬁciaries who underwent an incident surgery was 4.7%.
Patients experiencing major bleeding had longer hospital lengths
of stay (11.5 vs. 9.8 days, P < 0.01), longer ICU lengths of stay
(10 vs. 7.7 days, P < 0.01), were more likely to die in the hospital
(OR = 1.95, P < 0.01), and were responsible for signiﬁcantly
higher charges (+$18,512, P < 0.01) and reimbursements
(+$2642, P < 0.01). Over two years of follow-up, patients with
major bleeding were more likely to experience renal failure
(OR = 1.40, P = 0.06), were more likely to die (P < 0.01), and
incurred higher medical care costs (P < 0.05). CONCLUSION:
Patients who experienced major bleeding during CABG requiring
CPB tended to have poorer immediate and longer-term out-
comes. Results suggest that interventions to prevent major
bleeding during cardiac surgery may diminish or prevent these
negative clinical and economic outcomes.
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CHF PATIENTS ON ACE INHIBITORS
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OBJECTIVE: Aspirin use may negatively interact with the effect
of ACE inhibitors in treating heart failure. Hence, we sought to
determine whether aspirin increases the risk of heart failure
hospitalizations in non-elderly CHF patients on ACE Inhibitors.
METHODS: A retrospective analysis of the 2001 Georgia Med-
icaid claims data was performed. Patients between 18–64 years
of age who received a diagnosis of CHF (ICD-9 CM = 428.XX)
and ﬁlled at least one prescription for ACE Inhibitors between
January 1, 2001 and June 30, 2001 were included in the study.
Among these patients, those receiving aspirin were classiﬁed as
the exposed group and patients not receiving aspirin were clas-
siﬁed as the unexposed group. Hospitalization due to heart
failure was assessed between July 1, 2001 and December 31,
2001. Multi-variable logistic regression provided adjusted esti-
mates of the aspirin effect, with nonusers as the reference group,
after controlling for demographic factors, co-morbidities and
co-medications. RESULTS: One thousand four hundred fourteen
patients were identiﬁed. The total number of aspirin users was
178 (12.58%). Average age was 51.36 years and most patients
were females (66.5%). Also, most of the selected patients were
African Americans (57.1%). The unadjusted odds ratio for
exposure to aspirin was 1.798 (95% CI 1.097–2.896) and
the adjusted odds ratio was 1.782 (95% CI 1.074–3.009).
CONCLUSION: Aspirin use was associated with a greater risk
of hospitalization due to HF in patients taking ACE Inhibitors.
Hence, even in non-elderly CHF patients, a caution should be
exercised when prescribing aspirin concomitantly with ACE
inhibitors.
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OBJECTIVE: This study evaluated real world outcomes of
A1C and weight in patients with type-2 diabetes (T2DM) ini-
tiating exenatide therapy. METHODS: Patient data were
extracted from the General Electric (GE) electronic medical
record (EMR) research database from January 1, 2000 through
September 30, 2007. Patients were 18 years old with T2DM
deﬁned by ICD-9 codes, 2 fasting blood glucose levels
126 mg/dL, or glycosylated hemoglobin (A1C) over 7.0%.
Patients had prescription orders in the previous 395 d for met-
formin (MET), a sulfonylurea (SU) or a thiazolidinedione
(TZD) as monotherapy or in combination. Baseline A1C,
weight and BMI were documented 45 d prior to 15 d post-
exenatide initiation and 45 d at 6 mo post-exenatide initia-
tion. RESULTS: For the 2086 patients with 6 mo of follow-up
data, baseline mean (SD) A1C was 8.4  1.2%, weight was
243.4  54.8 lbs and BMI was 38.5  7.9 kg/m2. Upon initia-
tion of exenatide, 363 (17.4%), 147 (7.1%) and 84 (4.0%)
were on MET, SU or TZD monotherapy respectively, 524
(25.1%) and 257 (12.3%) were on MET with TZD or SU, and
711 (34.1%) were on all three. Overall A1C change at 6 mo
(n = 878) was -0.7%. When exenatide was added to MET, SU
or TZD monotherapy, changes were -0.9% (p < 0.0001),
-1.0% (p < 0.0001) and -0.8% (p < 0.0032) respectively. A1C
lowering ranged from -0.5% to -0.8% with multiple oral
antidiabetic drugs (OADs) (p < 0.0001). Overall weight loss
(n = 1784) was -6.1 lbs (p < 0.0001). In the 6 mo following
addition of exenatide to prior monotherapy, 14%, 23% and
45% of patients discontinued MET, SU and TZD respectively.
Similar discontinuations were seen in the multiple OAD groups.
CONCLUSION: The average baseline A1C (8.4%) and BMI
(38.5 kg/m2) is high in this primary care T2DM population,
suggesting difﬁculty in the real world to achieve A1C and body
weight goals. Exenatide therapy demonstrated signiﬁcant reduc-
tions in A1C and weight over 6 mo with decreases in concomi-
tant medications.
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OBJECTIVE:Neuropathic pain is a chronic condition that causes
functional impairment in many areas of life and it occurs fre-
quently with diabetes. The aim of this study was to analyze the
cost-effectiveness of different treatments in managing diabetic
peripheral neuropathy from the health care payer’s perspective.
METHODS: A four-state stochastic Markov model was per-
formed to estimate costs and effectiveness. The Markov model
includes several stages related to functional disability (mild-pain,
moderate-pain, severe-pain and death). Effectivenesswas assumed
as the percentage of patients with no or mild pain (pain score <4)
at the end of the follow-up period (one-year).Transition probabili-
ties were taken from national and international published litera-
ture. Comparators used in the assessment were carbamazepine
(200–600 mg/day), amitriptyline (100–150 mg/day), gabapen-
tin (2400–3600 mg/day) and pregabalin (300–600 mg/day).
Resource use and costs were obtained from hospital records
(n = 1000) from the Social Security Mexican Institute (IMSS)
and ofﬁcial institutional databases. Costs include emergency, out-
patient and inpatient services, drugs, procedures, etc. The model
was calibrated. Probabilistic sensitivity analyses were performed
employing bootstrapping techniques and acceptability curves
were constructed. RESULTS: The highest percentage of patients
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